https://www.selleckchem.com/pr....oducts/zilurgisertib
77 vs. 0.76, P = 0.009; in test cohort, 0.77 vs. 0.68, P 0.001), US (P 0.001), or clinical model (P 0.001). The CEUS model based on dynamic CEUS radiomics performed well in predicting early HCC recurrence after ablation. The combined model combining CEUS, US radiomics, and clinical factors could stratify the high risk of late recurrence. The CEUS model based on dynamic CEUS radiomics performed well in predicting early HCC recurrence after ablation. The combined model combining CEUS, US radiomics, and clinic
Like
Comment
Share
